Xenetic Biosciences, Inc. (XBIO)

Nasdaq: XBIO

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

Press Release

Santersus

Advancing Innovative Immune-Oncology Technologies

We are a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications.

More About Us

Targeting Neutrophil Extracellular Traps (NETs)

NETs are a driver of cancer progression and metastasis and can also contribute to resistance to chemotherapy, checkpoint inhibitors and radiotherapy.

DNase I Oncology Platform

Oncology platform aimed at improving cancer therapies with the opportunity to address multiple oncology indications, including pancreatic cancer and other solid tumors.

Pipeline

Latest News

Sep 16, 2026

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

Aug 07, 2026

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Investor Presentation

View Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates